Precision Peptide grants stock options and settles $125K debt with shares to CEO

Precision Peptide Company granted 600,000 restricted share units to a director and 1,100,000 stock options to directors, officers, and consultants, with options exercisable at $0.50 per share for three years. The company also settled $125,000 of debt owed to its CEO by issuing 300,000 common shares at a deemed price of $0.42 each. These moves are part of the company's incentive plan and debt management strategy, with shares issued subject to regulatory hold periods. This reflects ongoing efforts to align management incentives and manage liabilities as the company advances its peptide wellness products in North America.